Meyenburg Stiftung - Cancer Research Award Symposium

Wednesday 2 Apr 2025, 15:30 → 19:00 Europe/Berlin

 

 

Dear colleagues,

 

We are excited to invite you to this year’s Meyenburg Cancer Research Award ceremony, honoring Dr. Michel Sadelain, a visionary who transformed patients’ cells into “living drugs” that fight cancer.

 

Dr. Sadelain’s groundbreaking work on chimeric antigen receptor (CAR) T-cell therapy has fundamentally changed how we treat certain cancers. From the initial concept to FDA approval in 2017, his journey represents one of the most significant breakthroughs in modern oncology – giving hope to patients who previously had none. (See below for more information about Michel Sadelain and his work.)

 

Please join us for the Meyenburg Symposium and Award Ceremony at the German Cancer Research Center (DKFZ) in Heidelberg on April 2, 2025 at 3:30 p.m. Speakers include 

• Michel Sadelain (Columbia University, New York)
• Andreas Mackensen (Erlangen University Hospital)
• Fabrice André (Institut Gustave Roussy)
• Hafsa Munir (DKFZ and Helmholtz Institute for Translational Oncology Mainz)
• Franziska Blaeschke (DKFZ and Hopp Children's Cancer Center Heidelberg).

 

We look forward to your participation.

 

Very best wishes,

 

Stefan Fröhling

 

On behalf of the Board of the Meyenburg Foundation

Dr. Marion Meyenburg

Dr. Jörg Barth, Boehringer Ingelheim

Prof. Christiane Opitz, DKFZ

Prof. Stefan Pfister, DKFZ

 

 

 

About Michel Sadelain:

Revolutionary Science Meets Clinical Impact – Celebrating a Pioneer in Cancer Immunotherapy

 

Dr. Sadelain received his M.D. from the University of Paris, conducted his Ph.D. research at the University of Alberta, and completed postdoctoral work at the Whitehead Institute for Biomedical Research. He previously held the Stephen and Barbara Friedman Chair at Memorial Sloan Kettering Cancer Center, where he founded the Center for Cell Engineering. As the inaugural Director of Columbia University’s Initiative in Cell Engineering and Therapy and the Columbia University Irving Medical Center’s Cancer Cell Therapy Initiative, Dr. Sadelain continues to push boundaries in cellular engineering.

 

Dr. Sadelain’s remarkable contributions have been recognized with prestigious accolades, including the Breakthrough Prize for Life Sciences and the Canada Gairdner  International Award. He is a member of the American Academy of Arts and Sciences and the National Academy of 

Medicine of France. With the Meyenburg Cancer Research Award, we recognize Dr. Sadelain’s outstanding efforts to improve the clinical care of cancer patients through scientific inquiry, as well as his engaging and collaborative personality

 

 

Organizer:

 

Host: 

Prof. Dr. Stefan Fröhling 

DKFZ und NCT Heidelberg

 

In cooperation with:

15:30 → 15:40 Welcome

Speaker: Stefan Fröhling (DKFZ & National Center for Tumor Diseases (NCT) Heidelberg)

15:40 → 16:00 Targeting Stromal-Immune Interactions for Cancer Therapy

Speaker: Hafsa Munir (DKFZ & Helmholtz Institute for Translational Oncology (HI-TRON) Mainz)

16:00 → 16:20 Pooled CRISPR Screens: Reprogramming Therapeutic T Cells

Speaker: Franziska Blaeschke (DKFZ & Hopp Children’s Cancer Center (KiTZ) Heidelberg)

16:20 → 16:40 Coffee Break

16:40 → 17:10 Investigating Mechanisms of Action of New Cancer Drugs

Speaker: Fabrice André (Institut Gustave Roussy, Villejuif)

17:10 → 17:30 Laudation

Speaker: Andreas Mackensen (Erlangen University Hospital)

17:30 → 18:15 CAR T Cells: Living Drugs for Immunotherapy

Speaker: Michel Sadelain (Columbia University, New York)

18:15 → 18:30 Award Presentation to Michel Sadelain

Speaker: Marion Meyenburg

18:30 → 19:00 Reception